ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.

ÌÇÐÄ´«Ã½

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses. Blood advances Briercheck, E. L., Ravishankar, S., Ahmed, E. H., Carias Alvarado, C. C., Silva, O., Solórzano-Ortiz, E., Siliezar Tala, M. M., Stevenson, P. A., Xu, Y., Wohns, A. W., Enriquez-Vera, D., Barrionuevo, C., Yu, S. C., Freud, A. G., Weigel, C., Oakes, C. C., Weinstock, D. M., Klimaszewski, H. L., Ngankeu, A., Mutalima, N., Samayoa-Reyes, G., Newton, R., Rochford, R., Valvert, F., Natkunam, Y., Shustov, A., Baiocchi, R. A., Warren, E. H. 2024

Abstract

Epstein-Barr virus (EBV) is a potent carcinogen linked to hematologic and solid malignancies, causing significant global morbidity and mortality. Therapy using allogeneic EBV-specific lymphocytes shows promise in certain populations, but the impact of EBV genome variation on these strategies remains unexplored. To address this, we sequenced 217 EBV genomes, including hematologic malignancies from Guatemala, Peru, Malawi, and Taiwan, and analyzed them alongside 1,307 publicly available EBV genomes from cancer, non-malignant diseases, and healthy individuals across Africa, Asia, Europe, North America, and South America. These included the first NK/T-cell lymphoma (NKTCL) EBV genomes reported outside East Asia. Our findings indicate that previously proposed EBV genome variants specific to certain cancer types are more closely tied to geographic origin than cancer histology. This included variants previously reported to be specific to NKTCL but were prevalent in EBV genomes from other cancer types and healthy individuals in East Asia. After controlling for geographic region, we did identify multiple NKTCL-specific variants associated with a 7.8- to 21.9- fold increased risk. We also observed frequent variations in EBV genomes affecting peptide sequences previously reported to bind common MHC alleles. Finally, we found several non-synonymous variants spanning the coding sequences of current vaccine targets BALF4, BKRF2, BLLF1, BXLF2, BZLF1, and BZLF2. These results highlight the need to consider geographic variation in EBV genomes when devising strategies for exploiting adaptive immune responses against EBV-related cancers, ensuring greater global effectiveness and equity in prevention and treatment.

View details for

View details for